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Tracking of In-111-labeled human umbilical
tissue-derived cells (hUTC) in a rat model of
cerebral ischemia using SPECT imaging
Ali S Arbab1,2*, Christine Thiffault3, Bradford Navia4, Stephen J Victor4, Klaudyne Hong3, Li Zhang5, Quan Jiang5,
Nadimpalli RS Varma1, ASM Iskander1 and Michael Chopp5,6
Abstract
Background: In order to increase understanding of how infused cells work, it becomes important to track their
initial movement, localization, and engraftment efficiency following transplantation. However, the available in vivo
cell tracking techniques are suboptimal. The study objective was to determine the biodistribution of intravenously
administered Indium-111 (In-111) oxine labeled human umbilical tissue-derived cells (hUTC) in a rat model of
transient middle cerebral occlusion (tMCAo) using single photon emission computed tomography (SPECT).
Methods: Rats received 3 million In-111 labeled hUTC (i.v.) 48 hrs after tMCAo. Following the administration of
either hUTC or equivalent dose of In-111-oxine (18.5 MBq), animals underwent SPECT imaging on days 0, 1, and 3.
Radioactivity in various organs as well as in the stroke area and contralateral hemisphere was determined, decay
corrected and normalized to the total (whole body including head) radioactivity on day 0. Immunohistochemical
analysis was also performed to confirm the beneficial effects of hUTC on vascular and synaptic density, and
apoptosis.
Results: Most of the radioactivity (43.36±23.07% on day 0) trafficked to the lungs immediately following IV
administration of In-111 labeled hUTC (day 0) and decreased drastically to 8.81±7.75 and 4.01±4.52% on days 1 and
3 post-injection, respectively. In contrast, radioactivity measured in the lung of animals that received In-111-oxine
alone remained relatively unchanged from day 0 to day 1 (18.38±5.45% at day 0 to 12.59±5.94%) and decreased to
8.34±4.25% on day 3. Significantly higher radioactivity was observed in stroke areas of animals that received In-111
labeled hUTC indicating the presence of cells at the site of injury representing approximately 1% of total
administered dose. In addition, there was significant increase in vascular and synaptophysin immunoreactivity in
stroke areas of rats that received In-111 labeled hUTC.
Conclusions: The present studies showed the tracking of In-111 labeled hUTC to the sites of stroke in a rat model
of tMCAo using SPECT. Animals treated with In-111 labeled hUTC showed histological improvements, with higher
vascular and synaptic densities observed in the ischemic boundary zone (IBZ).
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Background
On average, every 40 seconds someone in the United
States has a stroke [1]. Each year, about 795,000 people
in the United States experience a new or recurrent
stroke. About 610,000 of these are first attacks, and
185,000 are recurrent attacks. Stroke mortality in 2008
accounted for about 1 of every 18 deaths in the United
States. Of all strokes, 87% are ischemic, 10% are intrace-
rebral hemorrhagic, and 3% are subarachnoid hemorrhagic
strokes [2].
The current treatment for ischemic stroke, tissue
plasminogen activator (TPA), while efficacious, is only
effective if it is administered within 4.5 hours of the
ischemic event [3,4]. Therefore, treatment with TPA
remains inadequate for patients who are unable to be
diagnosed and treated within that time frame. TPA
is also not appropriate for patients who suffer a
hemorrhagic stroke. Considering the limitations to
TPA and the high mortality rate of stroke patients,
there is a clear, unmet, need to reduce mortality rates,
restore neural function and extend the current window
of therapeutic opportunity. Effective treatments will
have to have a wide window of therapeutic opportun-
ity, address the neurological damage associated with
stroke and reduce disabilities that severely reduce qua-
lity of life for stroke patients. Cell-based therapy, a
novel approach to treating stroke, may offer significant
health benefits to patients [5-7].
Umbilical tissues and cord blood are sources of stem
cells. Cells from human umbilical cord blood (HUCBC)
have been extensively characterized [8-10] and most
show hematopoietic markers, such as CD34 and CD45.
Unlike human umbilical cord blood derived stem cells,
we have used human umbilical tissue-derived cells
(hUTC), which are CD34 and CD45 negative cells. The
detailed procedures of collection, separation and
characterization have been reported by others [11].
hUTC are identified as a potential technology for neu-
rorestorative and to improve functional outcomes fol-
lowing stroke. These cells have been characterized with
respect to the secretion of trophic, proangiogenic and
neuroprotective factors that could address the cellular
and structural damage to the brain post-stroke [11,12].
hUTC have recently been shown to be efficacious in ani-
mal models of diseases and an ability to improve neuro-
logical functional recovery in animal models of cerebral
ischemia [12]. hUTC may modulate restorative processes
including vascularization, and synaptic plasticity [1,12].
In order to increase understanding of how infused
cells work, it becomes important to track their initial
movement, localization, and engraftment efficiency fol-
lowing transplantation. However, the available in vivo
cell tracking techniques are suboptimal. For instance,
in vivo fluorescent or bioluminescent molecular and/or
cellular imaging techniques lack the resolution necessary
to localize sites of active cell migration and accumula-
tion. Superparamagnetic iron oxide (SPIO)-transfection
agent complexes using two FDA approved agents, ferum-
oxides (Fe) and Protamine sulfate (Pro) have been cre-
ated to label a broad range of mammalian cells. The
labeled cells can then be used as probes to localize physio-
logical or pathological processes using magnetic resonance
imaging (MRI) for high-resolution images in clinical set-
ting [13,14]. Cells labeled with the ferumoxides-
protamine sulfate (FePro) complexes can be imaged at
clinically relevant MRI fields using standard imaging
techniques and also at higher fields typical for animal
experiments. However, current MRI methods can not
differentiate focal hemorrhage from accumulated iron
positive cells. Many physiological and pathological con-
ditions like hemorrhage causes similar T2* effects on
MRI signal as iron containing contrast agents, and
therefore cause possible misinterpretation of iron con-
taining contrast agent accumulation. On the other
hand, cells labeled with radioisotopes such as In-111-
oxine can be tracked with confidence due to higher
sensitivity of nuclear medicine imaging modalities and
availability of hardware and software for whole body
scanning. Due to minimal background signal, accumu-
lation of In-111-labeled cells can also be quantified.
However, quantitative estimation of labeled cell con-
centration by MRI is under development and could
produce significant errors due to large background
signal from subject interfaces and pathological condi-
tions (hemorrhage etc.). These errors could be more
significant in the body than that in the brain.
The purposes of this study were to determine, whether
an in vivo imaging modality such as single photon emis-
sion computed tomography (SPECT) can be applied to
determine the migration and localization of In-111- la-
beled hUTC to the sites of stroke in a rat temporal middle
cerebral artery occlusion (MCAo) stroke model and to de-
termine the biodistribution of administered In-111 labeled
hUTC to various organs over time. For the future pro-
spect of clinical trials using hUTC, it is important to
know the whole body bio-distribution, organs of initial
homing and dynamics of redistribution, and specific ac-
cumulation profiles following systemic administration.
Materials and methods
Ethics statement
Animal experiments described in the manuscript were
approved by the animal care and user committee at
Henry Ford Health System according to the guidelines
and policies of office of laboratory animal welfare
(OLAW) and public health service, National Institutes
of Health. All the experiments were performed accor-
ding to the approved protocol. Human umbilical tissue-
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derived cells (hUTC) were isolated and expanded from
the umbilical cord of a single donor under full written
consent, as approved by the institutional review board
(IRB) of Lonza Inc (Allendale, NJ, USA) according to
USA FDA requirements. All consent forms are protected
as described in the approved IRB protocol.
Collection and preservation of Human Umbilical Tissue
Derived Cells (hUTC)
Human umbilical tissue-derived cells (hUTC) were iso-
lated and expanded from the umbilical cord of a single
donor under full consent, as previously described
[11,12]. These cells are positive for CD10, CD13, CD44,
CD73, CD90 and HLA-ABC (MHC I) but negative for
CD31, CD34, CD45, CD117 and HLA-DR, -DP and –DQ
(MHC II). Aliquots of the cell bank were thawed for
characterization testing that included viability, recovery,
sterility, endotoxin, mycoplasma, karyology and cell sur-
face marker immunophenotyping to ensure safety and
identity. hUTC were also tested at an early passage for
viral pathogens by a PCR-based method. Cells were
stored at cryogenic temperatures until labeling with In-
111 oxine.
Animal model
Seven to eight week-old male Wistar rats weighing 270–
300 g were purchased from Charles River Laboratories
International (Wilmington MA). Total of 25 animals were
included in this study. The animals utilized in this study
were handled and maintained according to protocols and
guidelines approved by the Institutional Animal Care and
Use Committee at Henry Ford Health System in accord-
ance with the current requirements of the Animal Welfare
Act (9 CFR) and the current standards set forth in the
Guide for the Care and Use of Laboratory Animals. Tem-
poral middle cerebral artery occlusion (tMCAo) was
induced in rats using the modified method of intraluminal
vascular occlusion as previously described [12]. Briefly,
rats were anesthetized with 3.5% isoflurane and main-
tained with 1-2% isoflurane in 70% N2O and 30% O2 using
a face mask. The right common carotid, external carotid
(ECA) and internal carotid (ICA) arteries were exposed. A
length of 4.0 monofilament nylon suture (~19 mm) with
its tip rounded by heating near a flame was introduced
from the ECA into the lumen of ICA until it blocked the
origin of the middle cerebral artery (MCA). Two hours
after MCA occlusion, animals were re-anesthetized with
isoflurane and reperfusion was achieved by withdrawal of
the suture until the tip cleared the lumen of the ICA.
Preparation of In-111 labeled hUTC and In-111 oxine
Based on an initial labeling and In-111 cellular retention
study results (supporting information S1), cells were la-
beled under adherent conditions. Cryopreserved cells
were thawed in a 37°C water bath, washed and resus-
pended in DMEM-low glucose media containing 15%
(vol/vol) FBS (HyClone, Logan UT), 100U/ml penicillin
and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA).
Six million cells were plated onto a T75 flask and culture
for 48 hrs. On the day of In-111 labeling, the cells were
washed twice with 5 ml of DMEM (serum free) and
2 ml of DMEM (serum free) was added to the flask.
Thirty seven MBq of In-111 oxine (in 1 ml in PBS,
Anazao Health Corp, Tampa FL) was added; adherent
cells were gently rocked and incubated at 37°C for 20–
25 min. The supernatant was removed and kept aside to
measure labeling efficiency (see below). The cells were
washed twice with PBS containing Ca2+/Mg2+ and the
collected supernatants were combined with the kept
aside supernatant. Cells were detached using TrypLE
(Invitrogen Corp, Carlsbad CA) and 7 ml DMEM con-
taining 20% FBS was added to neutralize TrypLE. Cells
were centrifuged 150 × g for 5 minutes at room
temperature and the supernatant was combined with the
previous washes (labeling efficiency; see below). Cells
were resuspended in 2 ml of a proprietary serum-free
cell delivery formulation, and the radioactivity content
was measured (see below). Cell viability was determined
using the Trypan blue exclusion method and viability of
80% or greater was used in this study. The radioactivity
content in the cell suspension and the combined washes
were counted using a dose calibrator (CRC 127R, Capin-
tec Inc., Ramsey NJ). Labeling efficiency was approxi-
mately 55%. Rats were administered (i.v. tail vein) either
3 million cells labeled with 18.5 MBq in a 2 ml volume
or vehicle (18.5 MBq Indium-111 oxine) 48 hrs post-
tMCAo. The number of administered cells was selected
based on our previous study [12]. Labeling efficiency
was calculated as follows:
% labeling efficiency or cell associated radioactivity =
(radioactivity in cell suspension) / (radioactivity in cell
suspension + total radioactivity in all supernatant and
cell washes)*100
Image acquisition
Animals were randomly assigned into two groups; 1)
animals receiving an intravenous (tail vein) administra-
tion of In-111-labeled hUTC 48 hrs post-tMCAo (n=13),
and 2) animals receiving an equal amount of In-111
oxine radioactivity 48 hrs post-tMCAo (n=12). Following
the administration of either In-111-labeled hUTC or In-
111-oxine alone, all animals underwent SPECT on days
0 (at least 1 hour after injection, 1–3 hours), 1 and 3
post administrations. Following anesthesia all animals
underwent SPECT imaging with a dedicated PRISM
3000 gamma camera fitted with custom built multi-
pinhole rat collimator (Bioscan, Washington DC), 360
degree rotation with 36 degree increments, 180 sec per
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projection, using 256x256 matrices with a field of view
of 4x6 cm. Both whole body and head only images were
acquired. Following acquisition, all images were trans-
ferred to a separate computer for reconstruction and
image analysis. Reconstruction was performed by dedi-
cated software supplied by Bioscan (HiSPECT, Washing-
ton DC). Image analysis was performed using Image J
software (NIH, Bethesda MD). A total of 25 animals
received either In-111-oxine alone (12 animals) or In-
111-labeled hUTC (13 animals). Animals in the vehicle
and treatment groups received an equivalent dose of
18.5 MBq of In-111. Maintaining the acquisition time
180 sec per projection, some animals underwent
SPECT acquisition on day 7, however a reliable 3D re-
construction was not possible due to In-111 physical/
biological decay. Therefore, we have not included
images from day 7.
Image analysis
Multiplanar reconstruction was performed using a slice
thickness of 0.8 mm. Volumetric images were created by
adding slices from the entire animal, dorsal to ventral.
Volumetric images of the ipsilateral (site of tMCAo) and
contralateral hemispheres were created by adding slices
of the brain but excluding the slices of bones and base
of the skull. However, to determine whole body radio-
activity, all slices of the head including bones, base of
the skull and brain were added and the radioactivity was
determined. Radioactivity in the animal (whole body in-
cluding head) on day 0 following administration of either
In-111-labeled hUTC or In-111-oxine alone (vehicle)
was considered the total administered dose. Regions of
interest (ROIs) were drawn on the ipsilateral (site of le-
sion) and contralateral intact brain excluding high radio-
activity measured in the petrous bones, lungs, liver,
spleen and both kidneys (Figures 1 and 2). Measured
radioactivity in various organs was reported as the per-
cent of the whole body radioactivity representing the
administered dose (decay corrected for In-111 half-life).
Percent administered dose was calculated for the lungs
(excluding heart radioactivity), liver, spleen and kidneys
on days 0, 1 and 3. Whole body radioactivity was also
determined for all animals on days 0, 1 and 3 following
administration of In-111-labeled hUTC and In-111-
oxine. The ROIs were created by an investigator who is
well versed in the anatomy of animals depicted on nu-
clear medicine studies. Although co-registration was not
possible due to unavailability of concurrent whole body
anatomical images, the investigator was careful enough
to encircle only the organ of interest.
Figure 1 Representative images of an animal administered 3 million In-111 labeled hUTC. Most of the cells trafficked to the lungs soon
after administration (day 0) and gradually decreased over time with increasing radioactivity observed in the liver. Note the early accumulation of
radioactivity in ipsilateral (right side) of the brain (tMCAo side) on day 0. IPL = ipsilateral, CNL = contralateral, R= right side.
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Neurobehavioral evaluation
All animals that received either 3 million In-111 labeled
hUTC or In-111-oxine only 48 hours following tMCAo
underwent neurobehavioral evaluation such as; modified
neurological severity score (mNSS), adhesive removal
test, and foot-fault test at pre, day 1, day 14, and weekly
thereafter for up to 90 days after tMCAo as previously
described [15-17]. Detail procedures of these tests have
been described in our recent publication [18].
Brain section preparation and evaluation
To determine the infarct volume, vascular and synaptic
densities at the sites of the lesion, animals were euthana-
tized at 12 weeks after the initiation of tMCAo. Follow-
ing euthanasia, rats were perfused with saline and 4%
paraformaldehyde. Then the brain was collected and
immersed in 4% paraformaldehyde. Seven 2 mm thick
paraffin blocks were made from each rat brain for histo-
chemical analysis.
Measurement of infarct area
One of each coronal paraffin section (6 μm thick) from
seven blocks was stained with hematoxylin and eosin
(H&E). The seven brain sections were traced using the
MCID computer imaging analysis system (InterFocus
Imaging Ltd, Linton, Cambridge). The lesion area was
measured indirectly by subtracting the intact area of the
ipsilateral hemisphere from the area of the contralateral
hemisphere [19]. The lesion volume is presented as a
volume percentage of the lesion compared to the contra-
lateral hemisphere.
Vascularization and synaptic density
A paraffin block was obtained from the center of the le-
sion, corresponding to coronal coordinates for bregma
−1~1 mm. A series of 6-μm-thick sections were cut
from this block for analysis by light microscopy (Olym-
pus model BH-2, Olympus America Inc., Center Valley
PA). To determine the vascular and synaptic densities
around the stroke areas in In-111-labeled hUTC and In-
111 oxine treated groups, antibodies against vonWillebrand
factor (vWF, 1:400, Dako, Carpinteria CA) and synapto-
physin (1:500, Chemicon, Billerica MA) were used to
identify vessels and synapses, respectively.
Apoptotic cell staining
The terminal deoxynucleotidyl transferase (TdT)–
mediated dUTP-biotin nick end labeling (TUNEL)
Figure 2 Representative images of an animal treated with In-111 oxine alone (vehicle). The radioactivity observed in the lung and liver
remained relatively constant over time. Note that there was no preferential increase in the radioactivity in the ipsilateral (right) brain (tMCAo side).
IPL = ipsilateral, CNL = contralateral, R = right side.
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method (in situ Apoptosis Detection Kit, Chemicon, Bill-
erica MA) was used to identify and assess apoptotic cells
in situ. The TUNEL method is based on the specific
binding of TdT to 3’-OH ends of DNA and the ensuing
synthesis of polydeoxynucleotide polymer cells. Staining
was performed according to procedures provided by the
manufacturer.
Presence of human cells and host macrophages
To confirm the migration and distribution of administered
hUTC in and around the stroke lesion, especially in ische-
mic boundary zone (IBZ), sections were also stained with
human cell specific marker such as β2-mitochondria (anti
human β2-mitochondria antibody, Chemicon, Billerica
MA). Human cell specific mitochondrial antibodies are
described in previous publications [20]. The antibody that
we used is also specific for human mitochondria and does
not react with rat or mouse (http://www.millipore.com/
catalogue/item/mab1273) [21,22]. To determine the pres-
ence of host macrophages at the sites of stroke and their
presence around the accumulated human specific cells,
sections were double stained with anti human β2-
mitochondria antibody (secondary antibody tagged with
Rhodamine) and anti rat macrophage antibody (CD68,
Santa Cruz, secondary antibody tagged with FITC) and
counter stained with DAPI.
Apoptotic cell, vascular and synaptic density
quantification
The number of apoptotic cells per section was counted
in the ipsilateral hemisphere. For measurement of vascu-
lar and synapse density, 8 fields of view from the IBZ
were digitized using a 40X objective and the MCID
computer imaging analysis system. The number of ves-
sels was counted throughout each field of view and was
reported as the density of vessels in the IBZ. For meas-
urement of synapse density, a threshold for the synapto-
physin immunoreactivity was selected based on the
contralateral homologous positive regions by using the
“set color threshold” feature in the analysis software.
The same threshold was applied to the same set of
images that were obtained at equal objectives and light
intensities. The data represent the mean area occupied
by synaptophysin immunoreactivity, expressed as a per-
centage of total scan area.
Data analysis
All data were expressed as mean ± SEM (standard error
of mean) unless indicated otherwise. SPECT data were
evaluated using repeated measure analysis of variance
(ANOVA) followed by post-hoc test Fisher’s PLSD, with
p value of ≤0.05 considered statistically significant. All
other histological analyses were also evaluated by stu-
dent t-test and a p-value of ≤0.05 was considered
significantly different. The global test using Generalize
Estimating Equation (GEE) was implemented to test the
group difference on functional recovery measured from
three behavioral tests and a p-value of ≤0.05 was consid-
ered significantly different.
Results
Labeling efficiency and viability (Additional file 1)
When hUTC were labeled in suspension following trypsi-
nization, viability at the end of the labeling procedure was
approximately 59-72% and viability did not improve over
time (46-51% at 24 hours). Therefore cells were labeled
under adherent condition whereby cell viability at the end
of the labeling period was higher (about 95%) and
remained high at 24 hours (70-72%) under in vitro condi-
tions. Cellular retention of radioactivity was also high in
cells that were labeled under adherent condition. With
this optimized method, a labeling efficiency of 59.3±2.35%
and cell viability of 89.98±3.62% was achieved at the end
of the labeling procedure.
Biodistribution of In-111 only and In-111 labeled hUTC in
different organs
Figures 1 and 2 show representative images of an animal
that received In-111-labeled hUTC or In-111-oxine
alone, respectively. Note the considerable changes in the
level of radioactivity in the lungs from day 0 to day 3
in animals that received In-111-labeled hUTC. In con-
trast, a similar pattern of changes in radioactivity was
not seen in animals that received In-111-oxine alone
and the level of radioactivity in the lung remained
relatively unchanged.
Figure 3 shows the decay corrected percent of admi-
nistered dose (radioactivity on day 0), present in various
organs over time following the administration of In-111-
labeled hUTC or In-111 oxine alone (vehicle) to rats.
Rapid clearance of radioactivity was observed from the
whole body in animals that received In-111-labeled
hUTC (Figure 3A). When the percent of administered
In-111-labeled hUTC dose was calculated for various
organs, most of the radioactivity was observed in the
lungs on day 0 following administration. The lung radio-
activity on day 0 was 43.36±23.07% of administered
dose. On days 1 and 3, the radioactivity in the lungs
decreased drastically to 8.81±7.75 and 4.01±4.52%, re-
spectively. In contrast, the animals that received In-111-
oxine alone showed 18.38±5.45% of administered dose
on day 0 in the lungs, which did not substantially de-
crease from day 1 (12.59±5.94%) to day 3 (8.34±4.25%)
(Figure 3B). The percent-administered dose remained
relatively stable in the liver (Figure 3C) for both In-111-
labeled hUTC (30.48±14.38, 36.23±9.72, 23.36±8.21% on
days 0, 1, and 3, respectively) and In-111 oxine alone
(22.89±8.05, 26.11±6.63, 28.32±7.83% on days 0, 1, and
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3, respectively). Similarly percent administered dose
measured in spleen also remained stable for both In-
111-labeled hUTC (5.17±2.37, 6.13±1.09, 4.21±0.57% on
days 0, 1, and 3, respectively) and In-111 oxine alone
(5.73±2.56, 7.40±1.24, 7.57±1.65% on days 0, 1, and 3,
respectively). The percent of administered dose mea-
sured in the kidney of rats administered In-111-labeled
hUTC was very similar to that observed in animals trea-
ted with In-111 only on days 0, 1 and 3 (Figure 3D), sug-
gesting that the kidneys were the route of free In-111
elimination.
One of the main goals of this study was to deter-
mine whether administered hUTC migrate to the sites
of stroke (right hemisphere). SPECT scanning was used
to determine the accumulation of In-111-labeled hUTC
at the site of stroke. Radioactivity in the left hemi-
sphere was considered to be non-specific for all ani-
mals; therefore, radioactivity in the right hemisphere
(stroke site) was normalized to the radioactivity mea-
sured in the left hemisphere (R/L). It is expected that
in rats that received In-111 oxine alone, radioactivity
would not accumulate preferentially in the site of le-
sion and that the radioactivity would not be increased
compared to contralateral hemisphere (R/L ratio near
one) in contrast to animals that received In-111-
labeled hUTC. It was hypothesized that animals admi-
nistered In-111-labeled hUTC would show significantly
higher R to L ratio due to specific migration of hUTC
to the stroke area. Figure 4A shows representative
images of the accumulation of radioactivity to the site
of the stroke lesion following the administration of In-
111-labeled hUTC to rats. The R/L ratio was signifi-
cantly higher (p<0.05) on days 0, 1, 3 in animals that
received In-111-labeled hUTC (1.24±0.29, 1.63±0.39,
1.75±0.59, respectively) compared to the animals that
received In-111 oxine alone (vehicle) (0.95±0.18, 1.13
±0.22, 1.16±0.29, respectively) (Figure 4B). The ratio
increased significantly (p=<0.01) from day 1 to day 3
in animals that received In-111 labeled hUTC; how-
ever, a similar pattern of radioactivity ratio was not
Figure 3 Biodistribution in the whole body, lungs, liver and kidneys. Relative percent radioactivity in the whole body (A), lungs (B), liver (C)
and kidneys (D) of rats that received In-111 oxine vehicle (n=12) or 3 million In-111 labeled hUTC (n=13) 48 hrs after tMCAo. Animals underwent
SPECT imaging at day 0, 1 and 3 post-administration and data was normalized to the body radioactivity content on day 0 and corrected for In-
111 half-life. WB = whole body, Dc = decay corrected. * = significant differences compared to day 0, # = significant difference between day 1
and 3.
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observed in animals administered In-111-oxine alone
(Figure 4B), indicating specific accumulation of cells at
the site of the lesion.
Neurobehavioral improvement following hUTC
administration
Due to loss of animals during 12–13 weeks follow up,
data from 11 animals that received In-111-labeled hUTC
cells and data from 10 animals that received In-111-
oxine only are included. Rats subjected to In-111 labeled
hUTC treatment 48 hrs after tMCAo exhibited signifi-
cant neurobehavioral improvements measured by mNSS,
adhesive removal test, and foot-fault test starting at day
14 and persisting to day 90 compared to vehicle (In-111-
oxine) treated rats (p<0.05, Generalize Estimating Equa-
tion test) (Table 1).
Figure 4 Accumulation of administered In-111 labeled hUTC in the stroke lesion compared to that of In-111 oxine treated animals.
Images were from two representative animals in respective groups in In-111 labeled hUTC (top panel) and In-111 oxine vehicle (bottom
panel). SPECT images showed higher radioactivity (A) in the lesions (ipsilateral side (dotted circle) and top panel) and the semi-quantitative
analysis showed increased in the ipsilateral to contralateral ratio in animals that received In-111 labeled hUTC (n=13) or In-111 oxine vehicle
(n=12) (B). * = significant differences compared to corresponding day 0, and # significant differences compared to corresponding In-111-labeled hUTC.
Table 1 Results of neurobehavioral testing in animals that received either In-111-oxine or 3 million In-111-labeled
hUTC (In-111 hUTC) 48 hours post-tMCAo
mNSS score Adhesive removal time score (sec) % Left foot-fault score
Days In-111 oxine In-111 hUTC In-111 oxine In-111 hUTC In-111 oxine In-111 hUTC
Mean±SD(n) Mean±SD(n) Mean±SD(n) Mean±SD(n) Mean±SD(n) Mean±SD(n)
1 11.2±0.63(10) 11.5±0.52(11) 115.4±5.18(10) 117.0±4.34(11) 36.6±3.24(10) 36.5±3.30(11)
7 ― ― ― ― ― ―
14 9.0±0.94(10) 8.5±0.69(11) 104.2±3.83(10) 100.4±6.83(11) 25.5±3.44(10) 24.3±2.94(11)
21 7.7±0.82(10) 6.9±0.54(11)* 91.1±9.88(10) 85.3±9.64(11)* 19.6±3.13(10) 17.4±3.11(11)*
28 7.2±0.79(10) 6.3±0.65(11)* 79.2±6.38(10) 66.0±9.95(11)* 17.9±2.64(10) 15.5±2.62(11)*
35 6.5±0.85(10) 5.5±0.69(11)* 71.1±5.11(10) 58.7±8.10(11)* 15.6±2.01(10) 13.5±1.81(11)*
42 6.2±0.79(10) 5.4±0.50(11)* 50.4±6.27(10) 41.3±9.31(11)* 14.0±2.49(10) 12.0±1.55(11)*
49 6.0±0.67(10) 5.1±0.30(11)* 45.6±6.83(10) 35.6±8.39(11)* 13.0±2.49(10) 11.0±1.34(11)*
56 5.6±0.52(10) 4.9±0.30(11)* 31.9±11.10(10) 21.5±9.25(11)* 12.2±2.39(10) 10.3±1.19(11)*
70 5.6±0.52(10) 4.8±0.60(11)* 78.4±13.76(10) 62.4±13.77(11)* 11.3±1.77(10) 9.9±1.14(11)*
84 5.4±0.52(10) 4.6±0.50(11)* 71.0±14.50(10) 45.2±6.73(11)* 10.9±1.91(10) 8.6±1.12(11)*
90 5.4±0.52(10) 4.6±0.50(11)* 61.3±12.73(10) 35.4±6.43(11)* 10.2±1.55(10) 8.5±0.93(11)*
The dada are expressed in mean±SD. Number of animals are indicated within parenthesis. * = significant differences.
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Histological analysis
Table 2 and Figure 5 summarize the histological findings
for the two treatment groups. We have previously
demonstrated that administration of hUTC effectively
improves neurological functional outcome without the
reduction of lesion volume [12]. In the present study, le-
sion volume was evaluated in rats that received 111 la-
beled hUTC or vehicle (In-111-oxine) 12 weeks post-
treatment.
No significant differences in the percent lesion volume
could be detected after 12 weeks in the brain of rats
administered with In-111-labeled hUTC 48 hrs after
stroke compared to In-111 oxine alone (Table 2).
Vascular density in the ischemic boundary zone (IBZ)
The density of blood vessels as monitored by vWF
immunoreactivity was significantly higher in the brains
of rats that received three million In-111-labeled hUTC
compared to In-111 oxine treated group (Figure 5) after
12 weeks following the administration of In-111 labeled
hUTC 48 hrs after stroke. These data are consistent with
our previous findings [12] demonstrating significantly
greater vascularization following the administration of
unlabeled hUTC to rats following tMCAo.
Synaptophysin expression in the IBZ
Synaptophysin, a presynaptic vesicle protein, is used as a
marker of synaptogenesis [23]. The expression of synap-
tophysin was significantly (p<0.05) higher in the IBZ of
animals treated at 48 hrs post-tMCAo with three million
In-111-labeled hUTC compared to In-111 oxine alone
(Figure 5). These data are consistent with our previous
findings [12] demonstrating increases in synaptic density
following the administration of unlabeled hUTC to rats
following tMCAo.
TUNEL positive cells in the brain
TUNEL histochemistry showed apoptotic cells with
typical dark brown, rounded or oval apoptotic bodies
(figure not shown). Scattered apoptotic cells were
present in the damaged tissue, the majority of which was
located in the IBZ. Although no significant differences in
the number of TUNEL positive cells in the ipsilateral
hemisphere were detected among the two groups, there
was a higher number of apoptotic cells present in ani-
mals that received In-111 oxine only (35.55±18.08 vs
20.37±11.55, In-111-oxine vs In-111 hUTC).
Presence of human cells and host macrophages in the IBZ
Figure 5 also shows the presence of β2-mitochondria
positive cells in the area of IBZ in animals that received
In-111-labeled hUTC. Similar dark brown cells were not
observed in animals that received In-111-oxine only.
Double stained sections showed clear separation of two
populations of cells. Macrophages (CD68+) are seen
mostly within the center of stroke as well as at IBZ.
There were very few human β2-mitochondria positive
cells in the IBZ. CD68+ cells were clearly separated from
human cells indicating that hUTC were not engulfed by
macrophages.
Discussion
The findings in the present study have clearly shown the
utilization of in vivo SPECT imaging for tracking In-
111-labeled hUTC to different organs following their
intravenous administration. The accumulation of In-
111-labeled hUTC and biodistribution differed from
that of In-111-oxine alone. The SPECT imaging showed
the migration and accumulation of hUTC to the site
of stroke lesion in a rat model of tMCAo, which
were detected as early as a few hours following IV
administration.
In-111 labeling
Labeling of cells under adherent conditions resulted in
higher viability and labeling efficiency. Although a lower
labeling efficiency was observed in cells labeled under an
adherent condition, long-term cellular viability (at
24 hours) and In-111 retention within cells was higher.
The lower cellular retention of In-111 when hUTC were
labeled in a suspension conditions was likely related to a
significantly higher death rate occurring at 24 hours
under the culture conditions. The higher death rate
observed in cells labeled in suspension compared to an
adherent condition might not be attributed to the
amount of In-111-oxine used (a similar dose of In-111-
oxine was used in both cases) but was instead related to
the lack of proper acclimatization of the cells to the
media soon after trypsinization. Similar results were
observed when cells were labeled soon after thawing
(data not shown). It appears that cells needed
acclimatization to the new media for a few hours prior
to labeling or needed to be attached before being labeled
with In-111 oxine. Although the cellular proliferation
Table 2 Histological measurements: Mean ± SD
Conditions In-111-oxine In-111 labeled hUTC
% Lesion volume (a) 27.61±14.56 (10) 26.68±15.19 (11)
vWF+ vessels/mm2 (b) 200.45±43.05 (10) 243.90±43.45 (11)*
% Synaptophysin+ area (c) 11.26±1.31 (10) 14.36±4.30 (11)*
TUNEL+ cells/mm2 (d) 35.55±18.08 (10) 20.37±11.55 (11)
N = number of rats/group is indicated in the brackets.
(a) Lesion volume is expressed as a percent compared to the contralateral
intact section of the brain.
(b) von Willebrand factor (vWF) is a marker for blood vessels. Density of vWF
vessels in IBZ (vessels/mm2).
(c) Synaptophysin, a marker of synapses, is expressed as a percent area in the
IBZ.
(d) Apoptosis is expressed as the number of apoptotic cells per mm2.
Asterisk indicates a significant difference.
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studies of In-111 labeled and unlabeled hUTC were not
the focus of this study, a transient decrease in the num-
ber of cells was observed following labeling with In-111
oxine for up to 3 days (cell viability was not different
from that of control and unlabeled cells), however, la-
beled cells showed a similar increase in cell number be-
tween days 3 and 14 compared to that of unlabeled cells
(end point of the study) (data not shown). The transient
difference in cell numbers might be attributed to the ef-
fect of ionizing radiation on the cell cycle [24]. This
observation was consistent with the dose response de-
crease in cell number and viability observed when cells
were exposed to increasing amounts of In-111 oxine
in vitro (Additional file 1) [24,25]. Yoon et al. [24]
demonstrated that rat bone marrow mesenchymal stem
cells (rMSC) labeled with 1–4 Bq In-111/cell did not
show a detrimental effect on the viability and prolifera-
tion status of In-111 labeled cells, however, the same
investigators reported that In-111, at levels of 4.4 Bq/
cell, caused a transient decrease in cellular proliferation
Figure 5 vWF, Synaptophysin, human cell specific staining (anti β2 mitochondrial antibody) and staining for rat macrophages. Upper
(first) panel: vWF staining showed significantly higher number of vWF positive cells in animals that received In-111 labeled hUTC. 2nd panel:
Similarly synaptophysin staining also showed significantly increased expression in animals that received In-111 hUTC. 3rd panel: A few human
specific β-mitochondria positive cells were observed in animals that received In-111 hUTC (black arrows) indicating presence of human cells.
Lower (fourth) panel: Sections are from IBZ in animals that received In-111-oxine (left) and In-111-labeled hUTC (right). CD68 positive cells (green
color, white arrows) are abundant in IBZ. However, a few human cells (Red color, yellow arrows) are seen in animals that received labeled cells. A
few red colored spots are seen in both sections (green arrows), which do not correspond to any nucleus (DAPI positive) are probably artifacts.
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with recovery of BrdU uptake by day 7. On the other
hand, cells exposed to a higher dose (11.1 Bq/cell)
caused permanent cell cycle arrest. The dose used in this
current study was 6.17 Bq/cell, which caused transient
decrease in cell number with full recovery observed after
3 days of culture consistent with published reports [24].
In addition, other investigators have shown a similar
effect of In-111 on the viability and proliferation of
CD34+ hematopoietic stem cells (HSC) [26].
IV administered hUTC, in vivo imaging and advantage of
nuclear medicine technique
Investigators have tracked In-111-labeled stem cells and
dendritic cells following IV administration in various
animal disease models as well as in human clinical stud-
ies [27-30]. Most investigations that used In-111-labeled
cells were primarily directed to the detection of cells in
myocardial infarction in animals or in humans. Investi-
gators also used intra-arterial injection of Tc-99m-
labeled bone marrow mononuclear cells in chronic
stroke patients to determine the distribution in the
stroke areas and in other organs [31,32]. These investi-
gators used autologous bone marrow cells, which were
not sorted for specific stem cell lineages and were
mixtures of different cell types. Makinen et al. has
used In-111-labeled cord blood mononuclear cells
(hematopoietic stem cells like cells) in stroke rats and
did not observe any migration of cells at the site of
stroke [33]. To our knowledge, this is the first study
that utilizes in vivo SPECT imaging to determine the
accumulation of In-111-labeled hUTC to the sites of
stroke in a rat model of tMCAo. The primary purpose
of these studies was to determine the initial distribution
and specific migration of IV administered hUTC to the
sites of stroke and other organs. We choose IV over
intra-arterial injection to avoid further blocking of small
patent vessels in stroke areas (micro thrombo-embolism
due to cell masses). The semi-quantitative analyses have
shown a differential distribution of In-111 labeled
hUTC in the lungs and liver over a 3–day period. The
findings are consistent with previous investigations
demonstrating that most of the administered cells traf-
ficked to the lungs soon after IV injection and then
redistributed to other organs over time [27,33-35]. The
pattern of distribution and the percent of administered
dose observed in various organs of In-111 labeled
hUTC treated animals differ considerably from rats
administered In-111 oxine alone. A considerable de-
crease in the percent of radioactivity was observed in
lungs of rats administered In-111 hUTC (from over
40% to 10%) within 24 hours that might be attributed
to the release and relocation of hUTC from the lungs
to other organs. The relocation of cells from lungs to
other organs is supported by data showing an increase
in the percent radioactivity detected in the liver on day
1 compare to day 0. Similar findings were also reported
by other investigators, where mesenchymal stem cells
showed relocation from lungs to the liver and spleen
[27,34,35]. The radioactivity seen in the lungs, liver and
spleen following administration of In-111-labeled hUTC
was thought to be due to the radioactivity associated
with the cells (not due to the release of In-111 bound
to cellular protein and subsequent labeling of adjacent
cells). In-111 oxine (oxyquinoline) complex is neutral
and lipid-soluble, which enables it to penetrate cell
membrane quickly. Once within the cell In-111
becomes firmly attached to cytoplasmic components,
which chelate In-111 more strongly than oxyquinoline.
Once In-111 is released as a result of cell lysis, it can-
not label surrounding cells because the In-111 complex
to cellular protein can no longer penetrate the cellular
membrane and therefore is excreted through the kidney
(see below). There was a significant difference in the
R/L ratios (ipsilateral/contralateral ratios) between the
groups of rats that received In-111 labeled hUTC or
In-111-oxine alone, indicating the distribution of
hUTC to the site of injury and accumulation over
time. Although it cannot be ascertained from SPECT
imaging whether In-111 was associated with cells,
results showed that a small percentage of the signal is
observed in the kidney, the proposed route of In-111
elimination, suggesting the presence of “free” In-111.
We did not further characterize the specificity of the
signal obtained in these animals. In a previous study, a
similar time dependent accumulation of neural pro-
genitor cells in stroke areas was observed following
intrathecal administration [36], although cellular mag-
netic resonance imaging (MRI) was applied to detect
the neural progenitor cells. In an ongoing investigation,
In-111-labeled endothelial progenitor cells show similar
time dependent accumulation to the sites of brain
tumor (unpublished data). In the current study, in vivo
imaging showed the specific accumulation and reten-
tion of administered hUTC to the sites of stroke,
which was also confirmed by the presence of human
cells in the stroke areas. Although we have not sacri-
ficed animals at an early time point to confirm the mi-
gration of human cells at the site of stroke, early
migration of umbilical cord blood derive mesenchymal
stem cells to the sites of stroke following IV and intra-
thecal administration has been demonstrated [37]. Dif-
ferent imaging modalities as well as in vivo detection
techniques have been used to determine the migration
and distribution of IV administered stem cells in vari-
ous organs or area of interests [38,39]. Our previous
studies as well as other investigators have shown that
the migration and accumulation of labeled cells to the
sites of lesions in various disease models using in vivo
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MRI, however, no data were provided on the tracking
and distribution of cells to other organs [13,40]. This
is because of large background signal from subject
interfaces in other organs and time to compensate loss
in SNR (signal to noise ratio) due to less sensitive big-
ger RF coil in small animal MRI system. Optical im-
aging systems are capable of imaging whole animals
but currently available imaging systems lack the
required resolution to identify the depth of incoming
signals and the sensitivity necessary to detect a small
number of accumulated cells. Attenuation (increased in
light scattering with depth) of fluorescent or biolumin-
escent signals is also an issue. Investigators also failed
to report detectable level of human cell markers using
rtPCR in various organs of interests following IV ad-
ministration of cells over time [27,41]. In this respect,
nuclear medicine imaging has an advantage over other
available techniques being highly sensitive as well as
having the option to use large field of view to cover
most of the animal body in a single scan and capable
to capture dynamic changes in the biodistribution of
cells in live animals. The current investigation showed
clear differences in the distribution patterns of radio-
activity at the sites of stroke and in various organs in
rats administered In-111 labeled hUTC as compared
to In-111-oxine only.
Significant changes in the radioactivity patterns were
observed in the whole body and the lungs. There was
also a difference in the percent of the radioactivity up-
take in the liver of In-111-labeled hUTC administered
group at day 3 compared to the In-111-oxine adminis-
tered animals. A possible explanation for these changes
in cell trafficking was that, following their intravenous
administration, the cells first passed through the lungs
and liver where they remained entrapped in the capillary
systems representing almost 80% of the administered
radioactive dose (based on whole body radioactivity on
day 0). Then the entrapped cells may be dislodged and
recirculate and accumulated to distal sites (such as
lesion site, bone marrow or organs of interest). A in-
crease in radioactivity in the spleen on day 1 was also
observed in this study. Some entrapped cells could have
been lysed. Radioactivity in lungs indicated clearly the
initial nonspecific entrapment with rapid clearance,
which is in agreement with other investigations
[27,34,35]. A negligible “free” In-111 in the circulation
was observed following IV administration of In-111 la-
beled hUTC as demonstrated by the absence of radio-
activity in the heart area whereas a strong radioactive
signal was observed in animals that received of In-111
oxine only. In addition, the lack of increase in radioactiv-
ity signal observed in the kidney at later time points was
also indicative of a negligible amount of the presence of
“free” In-111. Similar radioactivity signals in the kidneys
for both In-111-oxine only and In-111 labeled hUTC
groups suggested that the kidney was the route of excre-
tion of In-111 and represented a negligible amount. In
the present in vivo study also showed the specific accu-
mulation and retention of administered hUTC to the
sites of stroke, which was also confirmed by the presence
of human cells in the stroke areas. This is in agreement
with our previous studies, where the migration of admi-
nistered hUTC to the sites of stroke was demonstrated
by histochemical analyses [12]. Although the ability of
nuclear medicine techniques to track administered cells
is limited due to the short half-life of usable radiophar-
maceuticals for cell labeling, early migration as well as
redistribution of stem cells following IV administration
can be confidently assessed for at least a few days. More-
over, FDA approved radiopharmaceuticals are readily
available for cell labeling and for clinical imaging study
with less regulatory hurdles.
Specificity of cell associated activity vs free In-111
It was observed that a negligible amount of “free” In-111
existed in the circulation following IV administration of
In-111 labeled hUTC as demonstrated by the absence of
radioactivity in the heart area whereas a strong radio-
active signal was observed in animals that received of
In-111 oxine only. The strong radioactive signal
observed in the heart area of animals that received In-
111-oxine alone was probably due to red blood cells
(RBC) and plasma protein bound to In-111. Wistow
et al. [42] showed that 67% and 33% of radioactive oxine
(Tc-99 m-oxine) was bound to RBC and plasma protein,
respectively, when whole blood was incubated with Tc-
99 m-oxine. The protein and RBC bound to In-111 was
very stable and less that 1% excretes through feces and
urine when In-111 oxine alone was injected intraven-
ously. Thakur et al. [43] indicated that the efflux of In-
111 from labeled cells was very negligible and most of
the efflux happened within 5 minutes following the la-
beling procedure. Moreover, more than 90% of In-111
radioactivity was found to be associated with labeled
white blood cells (WBC) in patients 20 hours following
intravenous administration of In-111 labeled WBC [44].
Therefore, it can be concluded that the activity seen at
the sites of stroke in animals that received In-111 labeled
hUTC was due to the radioactivity associated with the
cells. It could be argued that transmigration of activity
from lungs to the lesions is attributed to the migration
of macrophages that had phagocytosed the In-111 la-
beled hUTC accumulated (impacted) in the capillary
processes of lung. Based on our previous experiences,
this is a very unlikely scenario. In previous studies we
have proven that IV administered stem cells that had
migrated to the sites of lesion were clearly distinguished
from the host macrophages. None of the human marker
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positive cells superimposed with host macrophages and
vice versa [45,46]. On the other hand, if the released In-
111 tagged with albumin and accumulated to the site of
stroke, we should have seen higher uptake in animals
that received In-111-oxine only. Compared to free In-
111, In-111-oxine has more avidity for serum albumin.
Double staining for both rat macrophage and human
marker in the current study demonstrated that human
cells were not engulfed by host macrophages, which is
also supported our previous findings [45,46].
Histological analysis
The primary aim of cell based therapy is to enhance the
recovery of function. The relationship between neuro-
logical function and the histological response in the
brain following stroke warrants investigation. Improve-
ment of functions as well as histochemical changes has
been reported following the administration of bone mar-
row derived stem cells in a rat model of stroke [47].
Similar to a previous report [12], increases in vascular
and synaptic densities in the vicinity of the ischemic
boundary zone (IBZ) have been reported following the
administration of In-111 labeled hUTC, although the le-
sion size and the number of apoptotic cells did not differ
significantly between the two groups of animals. Human
cell specific markers showed the presence of human cells
in the vicinity of the stroke in animals that received In-
111 labeled hUTC. With the added small amount of In-
111 radioactivity, we did not expect a reduction in the
efficacy of hUTC as demonstrated by the behavioral im-
provement such as modified neurological severity score
(mNSS), adhesive removal tests and foot fault measure-
ment and increases in markers of vascularization and
synaptic plasticity, consistent with the previously
reported study on the efficacy of hUTC on restorative
events [12]. These improvements of vascular and synap-
tic densities may be due to the bystander hUTC as well
as paracrine effects of the cells that have been reported
by others as well as by our group [7,12,47]. We have not
used immunosuppressant to reduce host’s response to
administered foreign cells. However, it has been noted
by different investigators that stromal cells as well as
umbilical tissue derived cells that express MHC I
molecules but show absence of MHC II molecular are
immunomodulatory and can be used in allogeneic
transplantation [48-50]. Histochemical analysis showing
separation of human marker positive and host macro-
phage marker positive cells also indicated the absence
of graft vs host reaction.
Conclusion
The present study demonstrated a useful technique to
label hUTC with In-111-oxine. It was demonstrated the
presence of signal from In-111 labeled hUTC to the site
of stroke in a rat model of tMCAo using in vivo SPECT
imaging. Animals treated with In-111 labeled hUTC
showed improvement at the cellular level in the IBZ as
indicated by the increased vascularization and synaptic
density in the treated tissues. In-111-oxine labeling is
safe and the labeling does not seem to have any detri-
mental effect on cell viability and therapeutic effects.
Additional file
Additional file 1: Optimization of hUTC labeling procedures using
In-111-oxine.
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